Vise Technologies Inc. Takes Position in Danaher Corporation $DHR

Vise Technologies Inc. purchased a new position in Danaher Corporation (NYSE:DHR) during the 2nd quarter, HoldingsChannel.com reports. The firm purchased 10,071 shares of the conglomerate’s stock, valued at approximately $1,989,000.

A number of other large investors also recently bought and sold shares of the business. Red Tortoise LLC lifted its position in shares of Danaher by 175.0% during the second quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock worth $30,000 after purchasing an additional 98 shares during the last quarter. Costello Asset Management INC purchased a new position in Danaher in the 1st quarter worth about $41,000. Ramirez Asset Management Inc. bought a new stake in Danaher during the 2nd quarter valued at about $40,000. Mowery & Schoenfeld Wealth Management LLC boosted its position in Danaher by 53.8% in the 1st quarter. Mowery & Schoenfeld Wealth Management LLC now owns 203 shares of the conglomerate’s stock valued at $42,000 after buying an additional 71 shares during the period. Finally, Strengthening Families & Communities LLC grew its stake in Danaher by 81.4% in the 1st quarter. Strengthening Families & Communities LLC now owns 254 shares of the conglomerate’s stock worth $52,000 after acquiring an additional 114 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

Shares of DHR opened at $215.80 on Wednesday. The company has a 50 day moving average of $204.36 and a two-hundred day moving average of $200.64. The company has a market cap of $152.43 billion, a price-to-earnings ratio of 44.49, a price-to-earnings-growth ratio of 3.28 and a beta of 0.81. The company has a quick ratio of 1.10, a current ratio of 1.52 and a debt-to-equity ratio of 0.33. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $258.23.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, October 21st. The conglomerate reported $1.89 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The firm had revenue of $6.05 billion during the quarter, compared to analysts’ expectations of $6 billion. During the same quarter last year, the firm earned $1.71 EPS. The business’s quarterly revenue was up 4.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, October 31st. Stockholders of record on Friday, September 26th were paid a dividend of $0.32 per share. The ex-dividend date was Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. Danaher’s payout ratio is presently 26.39%.

Insider Activity

In other Danaher news, Director Teri List sold 2,778 shares of the firm’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the transaction, the director owned 20,751 shares of the company’s stock, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 11.20% of the stock is currently owned by company insiders.

Analyst Ratings Changes

DHR has been the subject of a number of research reports. Wall Street Zen lowered Danaher from a “buy” rating to a “hold” rating in a report on Monday. JPMorgan Chase & Co. upped their target price on Danaher from $260.00 to $270.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. Barclays raised their price target on Danaher from $225.00 to $250.00 and gave the company an “overweight” rating in a research note on Wednesday, October 22nd. Guggenheim reaffirmed a “buy” rating and issued a $250.00 price objective on shares of Danaher in a research note on Wednesday, July 23rd. Finally, Wells Fargo & Company reiterated a “positive” rating on shares of Danaher in a report on Thursday, October 23rd. Eighteen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $243.39.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.